These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 30112193)
1. Does Rabbit Antithymocyte Globulin (Thymoglobuline®) Have a Role in Avoiding Delayed Graft Function in the Modern Era of Kidney Transplantation? Guirado L J Transplant; 2018; 2018():4524837. PubMed ID: 30112193 [TBL] [Abstract][Full Text] [Related]
2. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes. Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605 [TBL] [Abstract][Full Text] [Related]
3. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction. Patel SJ; Duhart BT; Krauss AG; Moore LW; Egidi MF; Amiri HS; Gaber LW; Gaber AO Transplantation; 2008 Jul; 86(2):313-20. PubMed ID: 18645496 [TBL] [Abstract][Full Text] [Related]
4. A CD3+ count-based thymoglobulin induction regimen permits delayed introduction of calcineurin inhibitors in kidney transplantation. Wang CJ; Tuffaha A; Zhang D; Diederich DA; Wetmore JB Clin Transplant; 2012; 26(6):900-9. PubMed ID: 22672562 [TBL] [Abstract][Full Text] [Related]
5. New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Mohty M; Bacigalupo A; Saliba F; Zuckermann A; Morelon E; Lebranchu Y Drugs; 2014 Sep; 74(14):1605-34. PubMed ID: 25164240 [TBL] [Abstract][Full Text] [Related]
6. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients. Dedinská I; Graňák K; Vnučák M; Skálová P; Laca Ĺ; Krivuš J; Galajda P; Mokáň M Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of antibody induction therapy in the current era of kidney transplantation. Opelz G; Unterrainer C; Süsal C; Döhler B Nephrol Dial Transplant; 2016 Oct; 31(10):1730-8. PubMed ID: 27190386 [TBL] [Abstract][Full Text] [Related]
9. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. Hertig A; Zuckermann A Transpl Immunol; 2015 Jun; 32(3):179-87. PubMed ID: 25936966 [TBL] [Abstract][Full Text] [Related]
10. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733 [TBL] [Abstract][Full Text] [Related]
11. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation. Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073 [TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Morgan RD; O'Callaghan JM; Knight SR; Morris PJ Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659 [TBL] [Abstract][Full Text] [Related]